Sonia Gera, Andrew Rearson, Robert J Gallop, Brynn E Marks
{"title":"Minimum Continuous Glucose Monitor Data Required to Assess Glycemic Control in Youth with Type 1 Diabetes.","authors":"Sonia Gera, Andrew Rearson, Robert J Gallop, Brynn E Marks","doi":"10.1089/dia.2025.0173","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Consensus guidelines recommend reviewing 14 days of continuous glucose monitor (CGM) data when assessing glycemia in people with type 1 diabetes (T1D). Adult studies have shown that 7 days of CGM data provide a reliable assessment of glycemia. <b><i>Objectives:</i></b> To understand the minimum amount of CGM data required to assess glycemia in the pediatric T1D population. <b><i>Methods:</i></b> Real-world Dexcom G6 CGM data were extracted from cloud-based CGM software for 8 time windows (3, 5, 7, 10, 14, 30, 60, and 90 days), all starting on March 1, 2023. Youth <21 years with T1D and ≥70% CGM active time in each window were included. Pearson correlation and interclass correlation coefficients (ICCs) between 14-day data and other windows were calculated. Differences in the percentage of youth within predetermined thresholds of 14-day CGM metrics (±0.3% glucose management indicator [GMI]; ±5% time in range [TIR]/time in tight range; ±1% time below range <70 and <54 mg/dL) were assessed using chi-squared analyses. Sub-analyses were conducted according to categorical groupings of 14-day TIR, coefficient of variation (CV), and age. <b><i>Results:</i></b> A total of 1316 youth were included (45.0% female, 76.9% non-Hispanic White, median age 14.6 years). Median 14-day CGM active time was 97.2% and GMI and TIR were 7.4% (7.0, 7.9) and 60.5% (48.6, 70.6), respectively. Pearson correlation coefficients and ICCs between 14-day and GMI and TIR for all 8 windows were >0.9; however, categorical agreement as defined by the percentage of subjects acceptable thresholds for GMI and TIR only exceeded 90% at 10 days. Although there was no difference in agreement for CGM metrics according to categorical groupings of age, agreement was stronger for youth with TIR ≥70% and CV <36%. <b><i>Conclusions:</i></b> Although 14 days of CGM data are considered the gold standard, assessing ∼9.6 days of data in youth with T1D provides a reliable assessment of glycemia. For youth with higher TIR (≥70%) and lower CV (<36%), 7-day CGM data may prove sufficient.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2025.0173","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Consensus guidelines recommend reviewing 14 days of continuous glucose monitor (CGM) data when assessing glycemia in people with type 1 diabetes (T1D). Adult studies have shown that 7 days of CGM data provide a reliable assessment of glycemia. Objectives: To understand the minimum amount of CGM data required to assess glycemia in the pediatric T1D population. Methods: Real-world Dexcom G6 CGM data were extracted from cloud-based CGM software for 8 time windows (3, 5, 7, 10, 14, 30, 60, and 90 days), all starting on March 1, 2023. Youth <21 years with T1D and ≥70% CGM active time in each window were included. Pearson correlation and interclass correlation coefficients (ICCs) between 14-day data and other windows were calculated. Differences in the percentage of youth within predetermined thresholds of 14-day CGM metrics (±0.3% glucose management indicator [GMI]; ±5% time in range [TIR]/time in tight range; ±1% time below range <70 and <54 mg/dL) were assessed using chi-squared analyses. Sub-analyses were conducted according to categorical groupings of 14-day TIR, coefficient of variation (CV), and age. Results: A total of 1316 youth were included (45.0% female, 76.9% non-Hispanic White, median age 14.6 years). Median 14-day CGM active time was 97.2% and GMI and TIR were 7.4% (7.0, 7.9) and 60.5% (48.6, 70.6), respectively. Pearson correlation coefficients and ICCs between 14-day and GMI and TIR for all 8 windows were >0.9; however, categorical agreement as defined by the percentage of subjects acceptable thresholds for GMI and TIR only exceeded 90% at 10 days. Although there was no difference in agreement for CGM metrics according to categorical groupings of age, agreement was stronger for youth with TIR ≥70% and CV <36%. Conclusions: Although 14 days of CGM data are considered the gold standard, assessing ∼9.6 days of data in youth with T1D provides a reliable assessment of glycemia. For youth with higher TIR (≥70%) and lower CV (<36%), 7-day CGM data may prove sufficient.
期刊介绍:
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.